Harnessing artificial intelligence for prostate cancer management
L Zhu, J Pan, W Mou, L Deng, Y Zhu, Y Wang… - Cell Reports …, 2024 - cell.com
Prostate cancer (PCa) is a common malignancy in males. The pathology review of PCa is
crucial for clinical decision-making, but traditional pathology review is labor intensive and …
crucial for clinical decision-making, but traditional pathology review is labor intensive and …
The Expression of Proto-Oncogene ETS-Related Gene (ERG) Plays a Central Role in the Oncogenic Mechanism Involved in the Development and Progression of …
E Khosh Kish, M Choudhry, Y Gamallat… - International journal of …, 2022 - mdpi.com
The ETS-related gene (ERG) is proto-oncogene that is classified as a member of the ETS
transcription factor family, which has been found to be consistently overexpressed in about …
transcription factor family, which has been found to be consistently overexpressed in about …
[HTML][HTML] Targeting N6-methyladenosine reader YTHDF1 with siRNA boosts antitumor immunity in NASH-HCC by inhibiting EZH2-IL-6 axis
L Wang, L Zhu, C Liang, X Huang, Z Liu, J Huo… - Journal of …, 2023 - Elsevier
Background & Aims RNA N 6-methyladenosine (m 6 A) reader protein YTHDF1 has been
implicated in cancer; however, its role in hepatocellular carcinoma (HCC), especially in non …
implicated in cancer; however, its role in hepatocellular carcinoma (HCC), especially in non …
New clinical trial design in precision medicine: discovery, development and direction
XP Duan, BD Qin, XD Jiao, K Liu, Z Wang… - Signal Transduction and …, 2024 - nature.com
In the era of precision medicine, it has been increasingly recognized that individuals with a
certain disease are complex and different from each other. Due to the underestimation of the …
certain disease are complex and different from each other. Due to the underestimation of the …
Transcending frontiers in prostate cancer: the role of oncometabolites on epigenetic regulation, CSCs, and tumor microenvironment to identify new therapeutic …
G Ambrosini, M Cordani, A Zarrabi… - Cell Communication and …, 2024 - Springer
Prostate cancer, as one of the most prevalent malignancies in males, exhibits an
approximate 5-year survival rate of 95% in advanced stages. A myriad of molecular events …
approximate 5-year survival rate of 95% in advanced stages. A myriad of molecular events …
EZH2 interacts with HP1BP3 to epigenetically activate WNT7B that promotes temozolomide resistance in glioblastoma
Glioblastoma (GBM) is the most lethal primary brain tumor in adults and harbors a
subpopulation of glioma stem cells (GSCs). Enhancer of Zeste Homolog 2 (EZH2), a histone …
subpopulation of glioma stem cells (GSCs). Enhancer of Zeste Homolog 2 (EZH2), a histone …
Past, current, and future strategies to target ERG fusion-positive prostate cancer
F Lorenzin, F Demichelis - Cancers, 2022 - mdpi.com
Simple Summary In addition to its role in development and in the vascular and
hematopoietic systems, ERG plays a central role in prostate cancer. Approximately 40–50 …
hematopoietic systems, ERG plays a central role in prostate cancer. Approximately 40–50 …
Epigenome-wide impact of MAT2A sustains the androgen-indifferent state and confers synthetic vulnerability in ERG fusion-positive prostate cancer
A Cacciatore, D Shinde, C Musumeci… - Nature …, 2024 - nature.com
Castration-resistant prostate cancer (CRPC) is a frequently occurring disease with adverse
clinical outcomes and limited therapeutic options. Here, we identify methionine …
clinical outcomes and limited therapeutic options. Here, we identify methionine …
Differences in the pathogenetic characteristics of prostate cancer in the transitional and peripheral zones and the possible molecular biological mechanisms
X Yu, R Liu, L Song, W Gao, X Wang, Y Zhang - Frontiers in Oncology, 2023 - frontiersin.org
Since the theory of modern anatomical partitioning of the prostate was proposed, the
differences in the incidence and pathological parameters of prostate cancer between the …
differences in the incidence and pathological parameters of prostate cancer between the …
Decoding oncofusions: unveiling mechanisms, clinical impact, and prospects for personalized cancer therapies
K Salokas, G Dashi, M Varjosalo - Cancers, 2023 - mdpi.com
Simple Summary Oncofusions, or cancer-associated fusion mutations, are driving forces in
cancer development. Advanced sequencing technologies have revolutionized their …
cancer development. Advanced sequencing technologies have revolutionized their …